Profile data is unavailable for this security.
About the company
Karolinska Development AB is a Sweden-based investment company. The Company provides capital to biotechnology firms, as well as develops and commercializes biotechnological products. Its activities are involved in a range of areas: oncology, infections and wound healing, women’s health, cardiovascular and hematology, medical equipment, diagnostics, pharmaceutical formulation, as well as implants, among others. The Company’s pharmaceuticals portfolio comprises: AXL1717 for non-small-cell lung carcinoma (NSCLC), APR-246 for ovarian cancer, Sevuparin for malaria, SHACT for pain relief at hysteroscopy and intrauterine device (IUD) insertion, and PC-mAB for acute coronary syndrome (ACS), among others. Furthermore, the Company controls a number of subsidiaries, such as Avaris AB, HBV Thernostica AB, KD Incentive AB, KDev Oncology AB and Limone AB.
- Revenue in SEK (TTM)1.94m
- Net income in SEK33.61m
- Incorporated2006
- Employees8.00
- LocationKarolinska Development ABTomtebodavagen 23 ASOLNA 171 65SwedenSWE
- Phone+46 852486070
- Websitehttps://www.karolinskadevelopment.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Episurf Medical AB | 11.00m | -92.10m | 203.35m | 25.00 | -- | 1.42 | -- | 18.49 | -0.266 | -0.266 | 0.0318 | 0.1861 | 0.0852 | -- | 5.24 | 392,857.20 | -71.42 | -47.46 | -81.48 | -52.01 | -- | -- | -838.18 | -1,019.29 | 2.54 | -- | 0.068 | -- | 53.62 | 19.78 | -22.64 | -- | -0.4158 | -- |
Arcoma AB | 171.89m | 9.40m | 204.38m | 31.00 | 21.74 | 3.87 | 12.39 | 1.19 | 0.713 | 0.713 | 13.04 | 4.01 | 1.81 | 3.71 | 6.93 | 5,544,871.00 | 9.92 | 1.12 | 18.49 | 2.01 | 36.83 | 37.66 | 5.47 | 0.7568 | 0.9788 | 11.95 | 0.0475 | 0.00 | 30.36 | 6.41 | 34.81 | -- | 22.75 | -- |
Nexstim Oyj | 82.72m | -15.15m | 214.70m | 37.00 | -- | 6.63 | -- | 2.60 | -0.1956 | -0.1956 | 1.09 | 0.4192 | 0.7211 | 0.2708 | 3.76 | 195,845.70 | -13.21 | -26.77 | -20.24 | -43.90 | 96.38 | 92.11 | -18.32 | -38.38 | 1.42 | -12.60 | 0.61 | -- | -23.94 | 22.08 | -201.58 | -- | 19.51 | -- |
SpectraCure AB (publ) | 2.65m | -21.06m | 247.20m | 13.00 | -- | 2.00 | -- | 93.28 | -0.2168 | -0.2168 | 0.0273 | 1.28 | 0.0178 | -- | 19.00 | 176,666.70 | -14.11 | -12.75 | -15.44 | -13.62 | 393.13 | 195.30 | -794.75 | -494.40 | -- | -- | 0.0499 | -- | -3.30 | -- | 19.46 | -- | -- | -- |
Scandinavian Medical Solutions A/S | 302.45m | 8.23m | 298.16m | 25.00 | 36.06 | 2.52 | 16.07 | 0.9858 | 0.1963 | 0.1963 | 7.22 | 2.81 | 1.38 | 1.89 | 11.35 | -- | 3.75 | -- | 6.15 | -- | 24.48 | -- | 2.72 | -- | 0.4307 | 5.54 | 0.3473 | -- | 72.98 | -- | 7.49 | -- | -- | -- |
Acarix AB | 5.84m | -76.29m | 301.20m | 9.00 | -- | 2.89 | -- | 51.58 | -0.1431 | -0.1431 | 0.0103 | 0.1069 | 0.0821 | 0.1257 | 3.51 | -- | -107.29 | -66.93 | -125.57 | -77.12 | 86.04 | 79.42 | -1,306.54 | -1,483.68 | 6.88 | -312.95 | 0.00 | -- | 7.20 | 43.55 | -1.11 | -- | -- | -- |
Micropos Medical AB (publ) | 1.77m | -23.76m | 355.51m | 9.00 | -- | 13.83 | -- | 200.63 | -0.258 | -0.258 | 0.0149 | 0.1692 | 0.0529 | 0.0999 | 0.7758 | 221,497.50 | -70.97 | -64.24 | -89.99 | -82.27 | 74.48 | 114.76 | -1,340.85 | -767.57 | 4.04 | -- | 0.0146 | -- | 50.23 | 5.94 | -26.57 | -- | -- | -- |
Boule Diagnostics AB | 576.03m | 26.98m | 396.10m | 233.00 | 14.85 | 0.7954 | 7.20 | 0.6876 | 0.6868 | 0.6868 | 14.79 | 12.82 | 0.7378 | 4.35 | 3.53 | 2,526,443.00 | 3.44 | 1.67 | 4.73 | 2.40 | 43.73 | 43.50 | 4.67 | 2.04 | 1.05 | 4.77 | 0.2638 | 42.24 | 4.24 | 6.13 | 96.24 | -9.45 | -9.74 | -- |
Karolinska Development AB | 1.94m | 33.61m | 406.63m | 8.00 | 12.20 | 0.3289 | 11.80 | 209.93 | 0.1245 | 0.1245 | 0.0072 | 4.62 | 0.0016 | -- | 1.66 | 242,125.00 | 2.71 | 3.37 | 2.73 | 3.83 | -- | -- | 1,734.95 | 1,466.36 | -- | -- | 0.0023 | 0.00 | -12.43 | -8.10 | 106.11 | -29.31 | -- | -- |
Bioretec Oy | 44.60m | -43.25m | 603.58m | 37.00 | -- | 6.17 | -- | 13.53 | -0.1984 | -0.1984 | 0.2047 | 0.4213 | 0.5524 | 1.46 | 3.68 | 105,594.60 | -53.58 | -67.11 | -65.75 | -97.60 | 69.85 | 70.97 | -96.98 | -134.05 | 4.86 | -4.02 | 0.0754 | -- | 32.77 | 19.77 | -56.82 | -- | -- | -- |
BrainCool AB (publ) | 29.15m | -57.05m | 608.14m | 22.00 | -- | 5.01 | -- | 20.87 | -0.2848 | -0.2848 | 0.1465 | 0.4792 | 0.2418 | 2.09 | 3.32 | 1,214,417.00 | -47.34 | -47.14 | -56.18 | -70.16 | -50.61 | -149.77 | -195.75 | -391.45 | 0.7253 | -7.34 | 0.00 | -- | 32.06 | 78.35 | -34.34 | -- | -11.63 | -- |
Holder | Shares | % Held |
---|---|---|
Swedbank Robur Fonder ABas of 29 Feb 2024 | 8.75m | 3.27% |
Handelsbanken Fonder ABas of 30 Apr 2024 | 1.50m | 0.56% |
Skandia Investment Management ABas of 28 Mar 2024 | 1.13m | 0.42% |
SEB Investment Management ABas of 30 Apr 2024 | 1.06m | 0.40% |
FCG Fonder ABas of 31 Dec 2023 | 668.07k | 0.25% |
Storebrand Asset Management ASas of 31 Jan 2024 | 249.49k | 0.09% |
Equinor Asset Management ASAas of 31 Dec 2023 | 54.30k | 0.02% |
Skandia Fonder ABas of 28 Mar 2024 | 43.90k | 0.02% |
Case Kapitalf�rvaltning ABas of 30 Nov 2022 | 18.70k | 0.01% |
Tredje AP-fondenas of 31 Dec 2021 | 0.00 | 0.00% |